Company: NCEL
Filing Date: 2025-06-30
Form Type: 6-K
Source: 0001213900-25-059248
Chunk: 1

Company: NewcelX Ltd.
Filing Date: 2025-06-30
Form: 6-K
Chunk 1
---
In addition, on June 26,
2025, the Company and Alpha Capital Anstalt, or Alpha, entered into a side letter pursuant to which the Company agreed to issue Alpha
pre-funded warrants to purchase 485,000 common shares in lieu of the Company’s prior agreement, contained in the Securities Purchase
Agreement, to issue Alpha 435,000 preferred shares (or their equivalent) to compensate Alpha for certain price protection issuances and
registration obligations.

The securities are being
offered pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended,
or the Securities Act, and Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities
Act or applicable state securities laws. Accordingly, once issued, the securities may not be offered or sold in the United States except
pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and
such applicable state securities laws.

Press Release

On June 30, 2025, the Company issued
a press release titled: “NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing.” A
copy of this press release is furnished herewith as Exhibit 99.5.

<div align='center'>1

EXHIBIT INDEX</div>

| Exhibit No. 
 99.1        
 99.2        |     | Document Description                                                                                                                                                                                               
 Form of Securities Purchase Agreement, dated March 27, 2025, by and between NLS Pharmaceutics and the certain purchasers thereto (filed as Exhibit 99.1 to Form 6-K (File No. 001-39957) filed on March 31, 2025). 
 Amendment to Securities Purchase Agreement, dated June 26, 2025, between NLS Pharmaceutics and the certain purchaser thereto.                                                                                      |
|:------------|:----|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 99.3        |     | Form of Common Warrant.                                                                                                                                                                                            |
| 99.4        |     | Side Letter.                                                                                                                                                                                                       |
| 99.5        |     | Form of Pre-Funded Warrant (filed as Exhibit 99.4 to Form 6-K (File No. 001-39957) filed on March 31, 2025).                                                                                                       |
| 99.